Clinical Trial Update: Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma [NA]

View source ↗

Summary

A completed compassionate-use study investigates a combination of asparaginase and pembrolizumab for nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Asparaginase (asparaginase)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Nasopharyngeal Carcinoma (NPC) | NA | Status: COMPLETED